Shardul Amarchand Mangaldas & Co. Advised Biocon Limited In Its USD 1.2 Billion Acquisition Of Shares In Biocon Biologics Limited

Shardul Amarchand Mangaldas & Co. Advised Biocon Limited on Its USD 1.2 Billion Acquisition of Shares in Biocon Biologics Limited

The leading law firm in India, Shardul Amarchand Mangaldas & Co. (SAM) advised Biocon Limited (BL) and its subsidiary Biocon Biologics Limited (BBL) on their ~USD 1.2 billion integration, involving BL’s acquisition of minority shareholdings in BBL from Viatris, Serum Institute Lifesciences, Tata Capital Growth Fund II, and True North.

The SAM transaction team advising BL and BBL was led by Raghubir Menon (Partner & Regional Practice Head – Mumbai, M&A and Private Equity, General Corporate) and Natashaa Shroff (Partner), with support from Tarumoy Chaudhuri (Partner), Rounak Agarwal (Principal Associate), Kriti Saraswat (Senior Associate), Sohini Banerjee (Associate), Mihira Jaggi (Associate), and Anushya Ramakrishna (Associate).

The SAM Competition Team was led by Shweta Shroff Chopra (Partner) and Supritha Prodaturi (Partner), supported by Parinita Kare (Senior Associate), Vasudha Verma (Associate), Saii S. (Associate), and Janhavi Jyoti S. (Associate).

The SAM Capital Markets Team included Prashant Gupta (Partner & National Practice Head – Capital Markets), Ruth Chenchiah (Partner), and Debolina Mitra (Senior Associate).

The SAM Banking & Finance Team comprised Shubhangi Garg (Partner) and Ansh Jain (Associate).

The SAM Securities Team included Yogesh Chande (Partner) and Anushri Mandal (Associate).

Click to know more about Shardul Amarchand Mangaldas & Co.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.